IRIS II study: The IRIS II score - Assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes

Diabetic Medicine

Volumn 21, Issue 10, 2004, Pages 1149-1153

  Forst, Thomas ^a   Standl, E ^b   Hohberg, C ^a   Konrad, T ^c   Schulze, J ^d   Strotmann, H J ^a   Lubben G ^e   Pahler, S ^a   Bachinger, A ^f   Langenfeld, M ^a   Pfutzner A ^a  

^a Institute for Clinical Research and Development   (Germany)

^b INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^c Institute for Metabolic Research   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e Takeda Pharma GmbH   (Germany)

^f Omnicare Clinical Research   (Germany)

Author keywords

Cardiovascular risk; Clinical score; Diabetes mellitus Type 2; Insulin resistance

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; HOMA IR SCORE; HUMAN; INSULIN RESISTANCE; INTERMETHOD COMPARISON; INTRAVENOUS GLUCOSE TOLERANCE TEST; IRIS II SCORE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SCORING SYSTEM; VALIDATION PROCESS;

ALGORITHMS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 6344291695     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01298.x     Document Type: Article

References (30)

1. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 1643-1649.
2. Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562-568.
3. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321: 337-343.
4. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990; 113: 909-915.
5. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22: 36-52.
6. Steinberg HO, Baron ADH. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623-634.
7. Laakso M. Insulin resistance and its impact on the approach to therapy of type 2 diabetes. Int J Clin Pract Suppl 2001; 121: 8-12.
8. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
9. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995; 96: 354-360.
10. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998; 47: 810-814.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
12. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 2000; 17: 299-307.
13. Rihl J, Biermann E, Standl E. Insulinresistenz und Typ-2-Diabetes: Die IRIS-Studie. Diabetes Stoffwechsel 2002; 11: 150-158.
14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
15. Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 1990; 71: 1508-1518.
16. Konrad T, Vicini P, Kusterer K, Hoflich A, Assadkhani A, Bohles HJ et al. α-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999; 22: 280-287.
17. Brun JF, Guintrand-Hugret R, Boegner C, Bouix O, Orsetti A. Influence of short-term submaximal exercise on parameters of glucose assimilation analyzed with the minimal model. Metabolism 1995; 44: 833-840.
18. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981; 68: 1456-1467.
19. Fleiss JL. Measuring agreement between two judges on the presence or absence of a trait. Biometrics 1975; 31: 651-659.
20. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 1989; 38: 1512-1527.
21. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993; 13: 1865-1873.
22. Birkeland KI, Kilhovd B, Thorsby P, Torjesin PA, Ganss R, Vaaler S et al. Heterogeneity of non-insulin-dependent diabetes expressed as variability in insulin sensitivity, β-cell function and cardiovascular risk profile. Diabet Med 2003; 20: 37-45.
23. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L et al. HOMA-Estimated insulin resistance is an independent predictor of cardiovascular disease in Type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25: 1135-1141.
24. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002; 25: 1177-1184.
25. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ceirculation 1996; 93: 1809-1817.
26. Haffner SM, Mykkanen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR. Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetes 1993; 42: 1297-1302.
27. Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Chen YD et al. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes 1994; 43: 1114-1121.
28. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527-534.
29. Beard JC, Bergman RN, Ward WK, Porte D Jr. The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values. Diabetes 1986; 35: 362-369.
30. Wagenknecht LE, D'Agostino RB Jr, Haffner SM, Savage PJ, Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1998; 21: 1812-1818.